Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.200
+0.080 (2.56%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Kiora Pharmaceuticals Employees
Kiora Pharmaceuticals had 12 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,335,000
Profits / Employee
$299,561
Market Cap
9.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
KPRX News
- 21 days ago - Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference - Newsfile Corp
- 4 weeks ago - Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 - Newsfile Corp
- 6 weeks ago - Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 - Newsfile Corp
- 2 months ago - Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Newsfile Corp
- 7 months ago - Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - Newsfile Corp